ReviewHuman vaccines & immunotherapeutics2016
Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 44 citations in OpenAlex.
- Why is announcement training more effective than conversation training for introducing HPV vaccination? A theory-based investigation.Implementation science : IS · 2018Trial
- Investigation of the clinical value of artificial intelligence-derived prognostic signature in cervical cancer based on machine learning algorithms.Discover oncology · 2026Article
- Development of a 12-Valent HPV L1 Virus-like Particle Vaccine Using an Enhanced Baculovirus Expression System.Vaccines · 2026Article
- Literature Review and Policy Recommendations for Single-Dose HPV Vaccination Schedule in China: Opportunities and Challenges.Vaccines · 2025Review
- HPV infection patterns and viral load distribution: implication on cervical cancer prevention in Western Kenya.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2025Article
- Epstein-Barr virus nuclear antigen 1 (EBNA1) increases the expression levels of MDM2 and MDM4 genes in HeLa cells: a review on MDM2 and MDM4 roles in cancer.BMC research notes · 2025Article
- A novel fluorescence immunoassay for the quantitative detection of HPV16 L1 antibodies in human serum samples using ZnCdSe/ZnS quantum dot-labeled antibodies.Microbiology spectrum · 2025Article
- Advancing Cervical Cancer Prevention Equity: Innovations in Self-Sampling and Digital Health Technologies Across Healthcare Settings.Diagnostics (Basel, Switzerland) · 2025Review
- Temporal trends of cervical cancer demographics: a CDC WONDER database study.Frontiers in oncology · 2025Article
- Interaction of High- and Low-Risk Human Papillomavirus Genotypes is Associated with a Reduced Risk of Developing Cervical Cancer.Infectious disorders drug targets · 2025Article
- Alpha-lipoic acid targetsActa biochimica et biophysica Sinica · 2024Article
- Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment.Cancers · 2024Article
- Human Papillomavirus (HPV) Infection and Risk Behavior in Vaccinated and Non-Vaccinated Paraguayan Young Women.Pathogens (Basel, Switzerland) · 2024Article
- Evaluation of HPV infection and presence of licensed HPV vaccine genotypes among genital warts in Foshan, China.Frontiers in microbiology · 2024Article
- HPV vaccine information, knowledge, attitude, and recommendation intention among male college students in China.Human vaccines & immunotherapeutics · 2023Article
- The status and challenges of HPV vaccine programme in China: an exploration of the related policy obstacles.BMJ global health · 2023Article
- Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape.Pharmaceuticals (Basel, Switzerland) · 2023Review
- HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK.Pathogens (Basel, Switzerland) · 2023Review
- Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances.International journal of nanomedicine · 2022Review
- Missed vaccinations and critical care admission: all you may wish to know or rediscover-a narrative review.Intensive care medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer causes significant morbidity and mortality worldwide. Most cervical cancers are associated with oncogenic human papillomavirus (HPV), and vaccination with any of 3 available HPV vaccines is anticipated to greatly reduce the burden of cervical cancer. This review provides an overview of the burden of HPV, the efficacy and clinical effectiveness of the bivalent (HPV 16, 18), quadrivalent (HPV 6, 11, 16, 18) and 9vHPV (HPV 6, 11, 16, 1831, 33, 45, 52, 58) vaccines in order to assess the anticipated impact on cervical cancer. All three vaccines show high efficacy in prevention of vaccine-specific HPV-type infection and associated high-grade cervical dysplasia in HPV-naïve women. Early clinical effectiveness data for the bivalent and quadrivalent vaccine demonstrate reduced rates of HPV 16 and 18 prevalence in vaccinated cohorts; data evaluating cervical dysplasia and cervical procedures as outcomes will shed further light on the clinical effectiveness of both vaccines. The bivalent vaccine has demonstrated cross-protection to non-vaccine HPV types, including the types in the 9vHPV vaccine. No clinical effectiveness data is yet available for the 9vHPV vaccine. While HPV vaccination has great promise to reduce cervical cancer morbidity and mortality, estimated benefits are largely theoretical at present. Large population-based clinical effectiveness studies will provide long-term immunogenicity and effectiveness, as well as assessment of cervical cancer as an endpoint, particularly as young vaccinated women enter the appropriate age range to initiate screening for cervical cancer. Strengthening screening and treatment programs will likely have the greatest impact in the short-term on cervical cancer morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.